Trial Profile
Phase II Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis (Residual Disease < 1cm) Associated With Ovarian Epithelial Cancer or Primary Peritoneal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-12 (Primary)
- Indications Cancer metastases; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Aug 2005 New trial record.